Published online Mar 15, 2024. doi: 10.4251/wjgo.v16.i3.1019
Peer-review started: October 30, 2023
First decision: December 6, 2023
Revised: December 16, 2023
Accepted: January 17, 2024
Article in press: January 17, 2024
Published online: March 15, 2024
Processing time: 133 Days and 23.8 Hours
Long non-coding RNA (lncRNA) GATA6-AS1 is known to be closely associated with tumorigenesis and development; however, its expression in gastric cancer and its role in the development of gastric cancer has not been fully explained. This study aimed to discuss the effects of GATA6-AS1 on the invasion, migration and proliferation of gastric malignant tumor cells by cell biology experiments, and investigate its mechanism of action.
Previous studies have reported that abnormal expression levels of lncRNA appear to influence the progression of gastric cancer, this paper first used bioinformatics analysis to screen out the lncRNA GATA6-AS1 that is abnormally expressed in gastric cancer tissues.
This study aimed to investigate the effects of GATA6-AS1 on the proliferation, invasion and migration of gastric cancer cells by cell biology experiments, and investigate its mechanism of action, so as to provide a basis for the early diagnosis and precise treatment of gastric cancer.
By constructing a lentivirus overexpression vector, we demonstrated that GATA6-AS1 acts as a tumor suppressor gene in gastric cancer. Next, we confirmed the binding of GATA6-AS1 and fat mass and obesity-associated protein (FTO) by performing RIP experiments.
This paper first used bioinformatics analysis to screen out the lncRNA GATA6-AS1 that is abnormally expressed in gastric cancer tissues. Then, through experimental research on the biological function of GATA6-AS1, it was confirmed that GATA6-AS1 can inhibit the proliferation, invasion, and migration of gastric tumor cells, suggesting that GATA6-AS1 plays a role as an anti-oncogene in the occurrence and development of gastric cancer. Further analysis of the reasons for the downregulation of GATA6-AS1 expression confirmed that it was regulated by the m6A demethylase FTO, which is upregulated in gastric cancer.
During the occurrence and development of gastric cancer, the overexpression of FTO may inhibit the expression of GATA6-AS1, thus promoting the proliferation and metastasis of gastric cancer.
GATA6-AS1 is expected to become a new indicator for diagnosing gastric cancer and predicting tumor recurrence, which has important clinical significance.